Laronidase

DB00090ApprovedInvestigationalProtein Based TherapiesHydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

Laronidase is a form of recombinant human alpha-L-iduronidase used to treat Hurler and Hurler-Scheie forms of mucopolysaccharidosis, a genetic deficiency of alpha-L-iduronidase. Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.

Mechanism: Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.
Curator reviewed
Primary indication: For the treatment of mucopolysaccharidosisCurator reviewed · 3 structured indications
Formula / weight: C₃₁₆₀H₄₈₄₈N₈₉₈O₈₈₁S₁₂ · 69899.4 Da
First approval: Canada, 2024 · United States, 2003 · European Union, 2016
Also known as: alpha-L-Idosiduronase · Human Recombinant alpha-L-iduronidase · Laronidase (genetical recombination)
Brand names: Aldurazyme

Resolves to

Compound

UNIIWP58SVM6R4CAS210589-09-6ChEMBLCHEMBL1201595

Clinical / RWD

RxNorm392509ATCA16AB05PharmGKBPA164776670

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

12Marketed productsAcross 9 countries and 5 labellers

1ATC codeIncluding every combination product, plus 8 drug categories

7+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Laronidase, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account